Current limitations in cancer survival, stage, and duration assessment require improvements beyond physical indications and conventional approaches. Improvements in patient care are a constant goal of the medical field. Predicting early Hepatocellular Carcinoma (HCC) patients’ survival status and stage is crucial for treatment and prognosis. This study presents an innovative two-stage prognostic paradigm for hepatocellular carcinoma, rectifying the deficiencies of existing diagnostic techniques. The framework uses metrics like accuracy, precision, recall, AUC, and F1 score to evaluate its ability to accurately predict a patient’s survival status (alive or dead). The framework accurately predicts patient survival status (Alive or Dead) by employing metrics such as accuracy, precision, recall, AUC, and F1 score for evaluation, while the subsequent component assesses AJCC staging levels (I, UNK, II, IV, IIIA, IIIC, IIIB, IIINOS) utilizing analogous metrics. Our experiments demonstrate that employing widely-used twelve machine learning models. By utilizing only a portion of SEER (Surveillance, Epidemiology, and End Results) data, we may obtain significantly distinct results. In survival analysis, Light Gradient Boosting Machine surpasses all other data-driven predictive models, achieving notable metrics: 89% accuracy, 87% precision, 89% recall, 87% F1-score and 86% of AUC. In the subsequent phase of forecasting AJCC stage levels, the Gradient Boosting model exhibits exceptional performance, achieving an accuracy of 98%, precision of 98%, recall of 98%, F1 score of 98%, and AUC of 100%. Our technique emphasizes critical factors influencing classification and regression choices within the two-stage hepatocellular carcinoma prognostic framework using interoperable model prediction analysis.